Reviewer's report

**Title:** Single Arm NCRI Feasibility Study of CHOP in Combination with Ofatumumab in Induction and Maintenance for Patients with Newly Diagnosed Richter's Syndrome

**Version:** 2  
**Date:** 30 December 2014

**Reviewer:** Bertrand Coiffier

**Reviewer's report:**

There is not any randomized study showing that ofatumomab does at least the same that rituximab in any disease. So, I do not see the benefit of using a more expensive drug that is not used in the real life. This study will be another phase II study not demonstrating anything and at best a conclusion of feasibility.

I think that labeling the study CHOP-OR is misleading because the R in CHOP-R refers to rituximab and this drug is not part of the study.